Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019

eqs_en 
0 0 07.10.19
DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png
 

DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Preliminary Results
QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019

07-Oct-2019 / 22:04 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

English Version

Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation

QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019

Venlo, The Netherlands, October 07, 2019 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces preliminary sales results for the third quarter of 2019 fall short of expectations.

For the third quarter of 2019, QIAGEN currently expects preliminary total net sales growth of about 3% at constant exchange rates (CER) compared to the outlook for about 4-5% CER growth, and mainly due to significantly weaker-than-expected developments in China. Total sales growth was about 6% CER excluding China sales. QIAGEN anticipates adjusted EPS within its outlook for approximately $0.35-0.36 CER.

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

ISIN: NL0012169213

Frankfurt Stock Exchange, regulated market (Prime Standard)

Contacts

John Gilardi

Vice President, Head of Corporate Communications and Investor Relations

+49 2103 29 11711 and +1 240 686 2222

[email protected]

07-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
Netherlands
Phone: +31 7735566 - 00
Fax: +31 77 35566-58
E-mail: [email protected]
Internet: www.qiagen.com
ISIN: NL0012169213
WKN: A2DKCH
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX
EQS News ID: 886525

 
End of Announcement DGAP News Service

886525  07-Oct-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=886525&application_name=news&site_id=sharewise

QIAGEN NV Aktie

40,47 €
-0,15 %
Die QIAGEN NV Aktie hat heute leichte Verluste von -0,15 % aufzuweisen.
Mehrere Buy-Einschätzungen für QIAGEN NV ohne eine einzige Sell-Einschätzung.
Ein positives, wenn auch bescheidenes, Potenzial für QIAGEN NV mit einem Kursziel von 47 € im Vergleich zum aktuellen Kurs von 40.47 €.
Mehr anzeigen
Like: 0
Teilen
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Rechtlicher Hinweis

Kommentare

Noch kein Mitglied? Jetzt kostenlos registrieren!